BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Citigroup

Research analysts at Citigroup began coverage on shares of BioNTech (NASDAQ:BNTX) in a research note issued on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $145.00 price target on the stock. Citigroup’s price objective would suggest a potential upside of 44.55% from the stock’s previous close.

Other analysts also recently issued research reports about the company. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $150.00 price objective on shares of BioNTech in a research report on Monday, November 18th. Wells Fargo & Company initiated coverage on BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective for the company. JPMorgan Chase & Co. cut their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Finally, Morgan Stanley cut their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Stock Performance

BNTX opened at $100.31 on Thursday. The company has a market cap of $24.05 billion, a PE ratio of -47.77 and a beta of 0.30. The stock has a 50-day moving average of $116.18 and a 200-day moving average of $113.04. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.90 EPS. As a group, equities research analysts forecast that BioNTech will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of BNTX. FMR LLC lifted its position in shares of BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares during the period. BNP Paribas Financial Markets bought a new position in shares of BioNTech during the 4th quarter worth approximately $69,999,000. Fred Alger Management LLC bought a new position in shares of BioNTech during the 3rd quarter worth approximately $59,485,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company’s stock worth $57,191,000 after buying an additional 433,388 shares during the period. Finally, Capital International Investors lifted its position in shares of BioNTech by 38.6% during the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock worth $161,304,000 after buying an additional 394,434 shares during the period. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.